Chicken Lips
21 Mar 2018
Oouch 13% fall My commiserations to all still holding but thats some drop today, plus 13%. In the heyday of Skp and Vec if a post here had said the joint value of the company will halve the value of the combined company and merger I would have thought they were nuts. It all looked so sublimely positive - that I bought into the merger and increased my already large holding from the two inot the combined one. Put some skin in the game. Combined at one point my top valued holdings - wow!! I'm so glad I got out or my hard earned (small) pension as it would be in tatters and life a lot harder. I hope L&G have some information we don't.Good luck to all holders over next few weeks. Its going to be choppy.
Ripley94
21 Mar 2018
Re: Topped up Rns results 15 % down set limit lifted @ 70p quickly down to 68p not looking such a good idea.. lol
Sprocket60
21 Mar 2018
Re: Takeover bid ? They are using this reporting period to write down assets mainly and get these out of the way. Clean sheet you may say. Just bought in as have L&G fund, so a takeover looks a good prospect at this drop. Would be looking at above £1 should an offer be made. Fingers crossed.
dave297
21 Mar 2018
Takeover bid ? Would certainly be my best option as I do not have the bottle to bail out at these levels, while being aware that we could be lower by the end of the week, & a takeover would present me with a fait accompli .I am sure our CEO & FD are considering their options & a disposal at a reasonable price is probably better for them ( with their few shares/options ) than walking for free .If HIK really do believe that our Advair generic will be approved & for sale early in 2020 they should be tempted to be part of a break up team as the sum of the parts must be worth substantially more than our current whole (or should it be hole)
d gaser
21 Mar 2018
Finals Synergies /benerfits of scale =buss words The accounts released to day are very hard to compare as they are using two different dates ,which in them self's throw up all kinds of inconsistence, for instance ,2016/17 year was only a nine month year ,and income was calculated on a on pro rate value, that came in at £183.6 m . Where as the income for 2017 Jan 1 to Dec 30 is a full 12 months, but it started later than the previous year, came in at £148m which is a fall for the year after adjustments. .Mark ups were up a little from 31.4% gross to 37.6% that's a increase of just 6% ,the industry average is around 60-70% mark up ,so there's lots more there to do .The words synergies and benefits of scale, seem to be the buss words in the full set of accounts , but what they actual mean is any bodies guess ,especially, as they are trying to use a 9 month year starting in march 2015 and finishing in Dec 2015 , against a 12 month year which started in Jan 1st 2017 and then finishing on the 30 Dec 2017 . These accounts do not fill me with hope for 2018 ,hopefully there's a buyer out there, who can see through the mist, and will come in with an offer we can't refuse .BE HAPPYDAVE 07
10 +000: Vectura Group 2017 Preliminary Results RNS Number : 3989I Vectura Group plc 21 March 2018 Vectura Group plc2017 Preliminary Results- Performance in-line with expectations, with strong in-market growth from key inhaled products -Chippenham, UK - 21 March 2018: Vectura Group plc (LSE: VEC) ("Vectura", "the Group", "the Company"
, an industry-leading inhaled product formulation, device design and development business, today announces its preliminary results for the year ended 31 December 2017. Financial highlights· Full year reported revenue of £148.0 million, in line with Board expectations (reported 9m 2016: £126.5 million) 2016 full-year proforma[1],[2] revenue was £183.6 million. 2017 reported revenue was lower due to reduced revenues from non-recurring sources[3] of £16.6 million in 2017 compared to £57.3 million in the 2016 proformao 2017 underlying2,[4] revenue was £131.4 million; +4.0% driven by the Group's key-inhaled productso 2017 underlying revenue from flutiform®, Ultibro® and Seebri® Breezhaler® +5.4% to £85.8 million· Strong annual in-market net sales growth from key products: flutiform® +11.8% (CER) and Ultibro® Breezhaler® +20.6% (CER)[5],[6]· Group reported revenue growth was moderated compared to in-market sales growth by previously-reported destocking in flutiform® and Ultibro® Breezhaler® supply chains, which had no impact on in-market sales momentum· IFRS-reported operating loss of £96.2 million, due to the impact of a full year, non-cash charge for amortisation and impairment of intangible assets of £109.7 million, arising from prior acquisitions (9m 2016: £44.5 million operating loss and £64.0 million amortisation charge)o Adjusted EBITDA2,[7] was ahead of expectations at £25.8 million profit (reported 9m 2016: £34.1 million profit), driven by in-line revenue performance, delivery of merger synergy savings and tight R&D cost management. R&D costs of £60.3 million were at the lower end of the guidance range (reported 9m 2016: £45.6 million)o The reduction in adjusted EBITDA versus reported 9m 2016 reflects a full year of R&D costs in 2017· Ongoing disciplined capital allocation and working capital management delivered strong operating cash inflows and the Group ended the year with a closing cash balance of £103.7 million (31 December 2016: £92.5 million) Operational highlightsRefocused pipeline investment with progression of key priority programmes· Inhaled generics o Two major new generics programmes added to the pipeline (VR2081 and VR410), with the potential for development of additional combination therapy (LAMA/LABA)o Following FDA interactions, Vectura is progressing the development of its Open-Inhale-Close devic
raptor66
21 Mar 2018
Re: Finals Today and dropped out of ftse250.
sadoldsod
21 Mar 2018
Re: Finals Today paid 441 million for skp now vec only worth 555 didn't the bod do well.
Chicken Lips
21 Mar 2018
Re: Finals Today It's difficult to see anything positive in there. NOthing about the merger and builds on synergies already made but lots about the duff aquisitions made since. Sentimentally I keep thinking I should be in but this management has made a complete Horlix of two perfectly or so it seemed good companies. I would resign.
dave297
21 Mar 2018
Directors Buying ? It will be interesting to see if they consider our current SP in in the bargain basement & take the opportunity to substantially increase their holdings
dave297
21 Mar 2018
Finals Today Interesting to see what The Market makes of the Finals & outlook statement -I conclude positively-but I am bound to as I am long !
dave297
20 Mar 2018
Legal & General Good to see them lifting their holding substantially ahead of our Results.
Matal
16 Mar 2018
Re: Promising The large UC trade in the auction is more likely due to index funds adjustments in reaction to VEC dropping out of the 250 as from Monday.
dave297
16 Mar 2018
Promising 9 mill trade late this afternoon & a firming SP could suggest a further closing of shorts ahead of the results next week & reasonably positive ( or better) perhaps our SP will recover to the heady heights of 100p +.Remaining optimistic as there is no alternative !
d gaser
16 Mar 2018
Teva FDA Approval for Adviar Feb 2017 I thought some of you might like to read this blogger , he confirms that Israel’s Teva Generic Pharmaceutical product is now on sale In the USA, as I previously stated, we might not like it, but it is ,and we have to accept that the Teva product is all ready taking market share from GSK . GSK them self's say in their end of year statement that their new one shot Breo product (which we all know about )is eating in to Advairs market, along with the new Generic offering ,they go on to say they will be pushing their new Breo product in future, in the hope it can replace Advair .We also know Sandoz and Hikma among others ,claim they will be the first true disk type generic Advair to hit the market, we also know, their are new and better products than Advair out there now, and doctors will be placing many of their patients onto those products . It's also now clear to me, that the Advair market is now shrinking, and will continue to do as more and better drugs come to the market .Advair is a drug that has run it's course ,and has now been over taken by new and better drugs ,unfortunately we missed the chance to cash in on this product earlier this year , I now look forward 2020 ,to see just how many generics there will be ,and what price they will be ,yes it going to be a very interesting time with regards to new products ,and generics of old products .How ever I fear the pricing is going to be very competitive, I just hope all this work pays off in the long run .As they say ,never put all your eggs in one basket BE HAPPYDAVE Teva won FDA approval in February of 2017 for their own version of London’s GlaxoSmithKline’s (GSK) Advair inhaler. It’s called Air Duo.Rather than utilizing a product like GSK’s Diskus as a delivery device, it utilizes the Respiclick inhaler, the same inhaler used for ProAir, Teva’s generic version of albuterol.While the product was approved in February, there were quite a few hurdles that needed to be jumped before the product was ready to be introduced to the market. Apparently, those hurdles have now been met, and the product is now on the market.Teva’s AirDuo Respiclick has the same two medicines as GSK’s Advair, which include the inhaled corticosteroid fluticasone and the long acting beta adrenergic salmeterol. Also approved by the FDA at the same time was ArmonAir Respiclick, Teva’s version of GSK’s fluticasone (Flovent). Both AirDuo and ArmonAir are approved for asthmatics ages 12 and older. However, the Air Duo dose of the salmeterol is a lower dose than what is available in Advair, so it is not exactly compatible with Advair.Still, it is cheaper. And so, this is good for asthmatics because it offers another less expensive option for those who cannot afford the brand products in this drug class (Advair, Symbicort, Dulera, and Breo). So, as long as you have your doctor’s approval, and so long as he/she writes the prescription, you might be able to try this medicine.This truly is good news in that this product offers a 69-81% discount compared to the price of Advair (which I will discuss in a moment). Recently, Mylan Pharmaceuticals generic version of Advair was rejected by the FDA. They probably just need to make a few changes before making another attempt at gaining approval. Sandoz, a division of Novartis that makes generic products, and Hikma Pharmaceuticals, of Jordan, also have generic versions of Advair that are closing in on FDA approval. All of these generic Advairs would be fully compatible with Advai. So, we’ll just have to wait a little longer to take advantage of these new generic Advair products. I personally will be very happy when one of these is on the market, as Advair is my favorite asthma controller medicine. What I don’t like is the price. If the price goes down, say, 50%, that’s $50 more I can spend on something fun (like baseball cards) as opposed to asthma medicine. So, hopefully this happens sooner rath
Matal
15 Mar 2018
Re: HIKMA I'm hoping VEC doesn't get get taken out. Their hasn't been any generic equivalent for Advair launched on the American market. Regardless of articles by journalists in the pharma press which I'm sure most have been well aware of... the Teva asthma inhaled asthma treatment is NOT a generic or in anyway some kind of cheaper substitute for Advair and has and will have... little or no impact on the substantial Advair market. Mylan was the first to find that the FDA have substantially changed their stance on the previous guidance they issued on any new so called generic replacement for Advair. Mylan were originally slightly in front of the que to get a substitute for Advair on the market and they were kicked completely out of the water by the FDA and have suffered a strightforward rejection. They have certainly and very publicly made themselves clear what they think about that! Also and despite Mylan and Hikma's experience... and despite being in a position to learn the lessons of Mylan and Hikma's experience by being MUCH later to the party... so was so was the Novartis /Sandoz attempts. Hikma is the only company that have been given encouragement to proceed and provided with the necessary guidance on what they must do achieve... and VERY importantly the FDA have made it clear they have no real problem with theGyroHayler device being used as a substitute for the Diskus. That is NOT the case for the other two companies devices! Despite the fact that it's going to be getting on for another two years before any possible market launch can take place... HIKMA and VEC have shown they are already in agreement to continue with this project... already have themselves organised... ready to start recruitment... and well on the way to putting in place the clinical endpoint study that has been requested by the FDA. That is a clear indication that they believe no-one is going to clear out the market from under them in-between times... and also, after what Hikma have just called many collaborative discussions over many months with the FDA over this issue.... it's a pretty good sign that they foresee no problems in being able to meet the FDA's requirements. If that hadn't been the case they would have called it quits on this product... imo.
